CD274 and non-small cell lung carcinoma: One of the first agents to evaluate the activity of IT in the CNS was Pembrolizumab, an anti-PD-1, has been approved as first-line setting for PDL1-positive advanced NSCLC patients according to KEYNOTE-0-24 study.